Teplizumab Regulatory Update; Sanofi Partners with Biocorp; Livongo Preferred on ESI; Omnipod Horizon Pivotal Trial Initiated; Glooko Partners with Mellitus Health
Here is a brief preview of this blast: A series of diabetes-related new items were observed today including an update on Provention Bio's teplizumab, a new Sanofi/Biocorp connected pen partnership, Livongo's preferred status on ESI, Insulet's Omnipod Horizon pivotal study, and more. Below FENIX provides insights and context from each respective news item.